David Lindstrom, MD
Family Medicine · Everett, WANPI 1902852569
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $803 and has fallen 51.8% since, to $387 in 2025. Among family medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$307
- Amgen$294
- Lilly USA, LLC$229
- Pfizer$208
- Johnson & Johnson$201
- Novo Nordisk$171
- plus $696 from 13 others
Across 4 payments — averaging $8774.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$35K
What the payments were for
- Food & beverage$2,100100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $307 |
| Amgen | 18 | $294 |
| Lilly USA, LLC | 14 | $229 |
| Pfizer | 10 | $208 |
| Johnson & Johnson | 9 | $201 |
| Novo Nordisk | 10 | $171 |
| GSK | 8 | $155 |
| Boehringer Ingelheim | 8 | $152 |
| AbbVie(2 entities) | 4 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Merck | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $43 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Agile Therapeutics, Inc. | 2 | $31 |
| Bausch Health US, LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Novartis | 1 | $13 |
| Gilead | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,106 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $122,900 |
| OzempicSemaglutide | 81 | $99,348 |
| JardianceEmpagliflozin | 71 | $84,897 |
| RybelsusSemaglutide | 20 | $39,673 |
| FarxigaDapagliflozin Propanediol | 25 | $35,222 |
| XareltoRivaroxaban | 21 | $33,294 |
| MyrbetriqMirabegron | 30 | $26,001 |
| TrulicityDulaglutide | 16 | $24,092 |
| InvokanaCanagliflozin | 19 | $20,583 |
| Atorvastatin Calcium | 523 | $6,907 |
| Rosuvastatin Calcium | 427 | $6,684 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $6,488 |
| PremarinEstrogens, Conjugated | 11 | $5,880 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,256 |
| BelsomraSuvorexant | 12 | $5,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $171 | $139,021101 claims |
| PfizerEliquis, Premarin, Paxlovid | $208 | $130,171121 claims |
| Boehringer IngelheimJardiance | $152 | $84,89771 claims |
| Johnson & JohnsonXarelto, Invokana | $201 | $53,87740 claims |
| AstraZenecaFarxiga | $307 | $35,22225 claims |
| Lilly USA, LLCTrulicity | $229 | $24,09216 claims |
| MerckBelsomra | $49 | $5,19112 claims |
| AbbVieSynthroid | $85 | $1,69127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Everett
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.